Literature DB >> 33420088

Spatiotemporal analysis of soluble aggregates and autophagy markers in the R6/2 mouse model.

M J Vijay Kumar1, Devanshi Shah1, Mridhula Giridharan2, Niraj Yadav2, Ravi Manjithaya3,4, James P Clement5.   

Abstract

Maintenance of cellular proteostasis is vital for post-mitotic cells like neurons to sustain normal physiological function and homeostasis, defects in which are established hallmarks of several age-related conditions like AD, PD, HD, and ALS. The Spatio-temporal accumulation of aggregated proteins in the form of inclusion bodies/plaques is one of the major characteristics of many neurodegenerative diseases, including Huntington's disease (HD). Toxic accumulation of HUNTINGTIN (HTT) aggregates in neurons bring about the aberrant phenotypes of HD, including severe motor dysfunction, dementia, and cognitive impairment at the organismal level, in an age-dependent manner. In several cellular and animal models, aggrephagy induction has been shown to clear aggregate-prone proteins like HTT and ameliorate disease pathology by conferring neuroprotection. In this study, we used the mouse model of HD, R6/2, to understand the pathogenicity of mHTT aggregates, primarily focusing on autophagy dysfunction. We report that basal autophagy is not altered in R6/2 mice, whilst being functional at a steady-state level in neurons. Moreover, we tested the efficacy of a known autophagy modulator, Nilotinib (Tasigna™), presently in clinical trials for PD, and HD, in curbing mHTT aggregate growth and their potential clearance, which was ineffective in both inducing autophagy and rescuing the pathological phenotypes in R6/2 mice.

Entities:  

Year:  2021        PMID: 33420088      PMCID: PMC7794371          DOI: 10.1038/s41598-020-78850-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  93 in total

1.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.

Authors:  Ana Maria Cuervo; Leonidas Stefanis; Ross Fredenburg; Peter T Lansbury; David Sulzer
Journal:  Science       Date:  2004-08-27       Impact factor: 47.728

2.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.

Authors:  Montserrat Arrasate; Siddhartha Mitra; Erik S Schweitzer; Mark R Segal; Steven Finkbeiner
Journal:  Nature       Date:  2004-10-14       Impact factor: 49.962

Review 3.  Proteostasis impairment in protein-misfolding and -aggregation diseases.

Authors:  Mark S Hipp; Sae-Hun Park; F Ulrich Hartl
Journal:  Trends Cell Biol       Date:  2014-06-16       Impact factor: 20.808

4.  Resveratrol protects neuronal-like cells expressing mutant Huntingtin from dopamine toxicity by rescuing ATG4-mediated autophagosome formation.

Authors:  Chiara Vidoni; Eleonora Secomandi; Andrea Castiglioni; Mariarosa A B Melone; Ciro Isidoro
Journal:  Neurochem Int       Date:  2017-05-19       Impact factor: 3.921

Review 5.  Sequestration of cellular interacting partners by protein aggregates: implication in a loss-of-function pathology.

Authors:  Hui Yang; Hong-Yu Hu
Journal:  FEBS J       Date:  2016-05-06       Impact factor: 5.542

6.  Formation and toxicity of soluble polyglutamine oligomers in living cells.

Authors:  Patrick Lajoie; Erik Lee Snapp
Journal:  PLoS One       Date:  2010-12-28       Impact factor: 3.240

7.  The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.

Authors:  Senthilkumar S Karuppagounder; Saurav Brahmachari; Yunjong Lee; Valina L Dawson; Ted M Dawson; Han Seok Ko
Journal:  Sci Rep       Date:  2014-05-02       Impact factor: 4.379

8.  Dynamic recruitment of ubiquitin to mutant huntingtin inclusion bodies.

Authors:  Katrin Juenemann; Anne H P Jansen; Luigi van Riel; Remco Merkx; Monique P C Mulder; Heeseon An; Alexander Statsyuk; Janine Kirstein; Huib Ovaa; Eric A Reits
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

9.  Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease.

Authors:  Nathaniel Safren; Amina El Ayadi; Lydia Chang; Chantelle E Terrillion; Todd D Gould; Darren F Boehning; Mervyn J Monteiro
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

Review 10.  Corticostriatal Dysfunction in Huntington's Disease: The Basics.

Authors:  Kendra D Bunner; George V Rebec
Journal:  Front Hum Neurosci       Date:  2016-06-28       Impact factor: 3.169

View more
  3 in total

Review 1.  Current Status of Autophagy Enhancers in Metabolic Disorders and Other Diseases.

Authors:  Kihyoun Park; Myung-Shik Lee
Journal:  Front Cell Dev Biol       Date:  2022-02-14

Review 2.  Emerging Role of NLRP3 Inflammasome/Pyroptosis in Huntington's Disease.

Authors:  Emanuela Paldino; Francesca Romana Fusco
Journal:  Int J Mol Sci       Date:  2022-07-28       Impact factor: 6.208

3.  The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis.

Authors:  Miguel Carracedo; Sven-Christian Pawelzik; Gonzalo Artiach; Marianne G Pouwer; Oscar Plunde; Peter Saliba-Gustafsson; Ewa Ehrenborg; Per Eriksson; Elsbet Pieterman; Leif Stenke; Hans M G Princen; Anders Franco-Cereceda; Magnus Bäck
Journal:  Br J Pharmacol       Date:  2022-07-19       Impact factor: 9.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.